Brief: Mesoblast

Mesoblast (MSB) has has confirmed media reports last Friday on positive preclinical results using its patented adult stem cell technology platform for the treatment of diabetes. Dr Ravi Krishnan, senior scientist at the Queen Elizabeth Hospital in Adelaide, led the study in collaboration with Mesoblast’s US-based associate company, Angioblast Systems.